ArticleGut microbes2025
Indole-3-lactic acid suppresses colorectal cancer via metabolic reprogramming.
Article in Gut microbes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Functional Training Mitigates Reduced Circulating Indole-3-Lactate Levels in Persons With Relapsing-Remitting Multiple Sclerosis.Acta physiologica (Oxford, England) · 2026Trial
- Lactobacillus plantarum-derived indole-3-lactic acid inhibits prostate cancer progression through ASF1B/ENO1 axis and remodels the tumor microenvironment to enhance anti-PD-1 therapy.Molecular biomedicine · 2026Article
- "Indole-3-acetic acid promotes differentiation while suppressing proliferation in human intestinal epithelial cells": a Letter to the Editor.Human cell · 2026Article
- Gut microbiota in health and disease.Molecular biomedicine · 2026Review
- In Situ Biosynthesis of Pd Nanocrystals in Bifidobacterium Bioreactor as Dual Immune Stimulators for Immuno-Chemodynamic Therapy of Cold Tumor.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Indole-3-acetic acid promotes differentiation while suppressing proliferation in human intestinal epithelial cells.Human cell · 2026Article
- Postbiotics as Multifunctional Bioactives: Mechanistic Insights and Translational Applications in Host Physiology and Microbial Ecosystem Modulation.Microorganisms · 2026Review
- Recent Advances in Natural Products for Colitis: Mechanisms and Translational Perspectives.Veterinary sciences · 2026Review
- Intratumoral microbiota in cancer: molecular mechanism and therapeutic strategies.Molecular biomedicine · 2026Review
- Decoding the crosstalk between ubiquitination and other post-translational modifications in cancer immunity: from mechanisms to clinical prospects.NPJ precision oncology · 2026Review
- Shaping death: how the microbiome regulates tumour cell demise and therapy response.Cancer metastasis reviews · 2026Review
- Polyphenolic nanodot-integrated spindle nanoplatform heals oral mucositis via microbiota restoration and glycolysis inhibition.Journal of nanobiotechnology · 2026Article
- Harnessing the Gut Microbiota to Improve Cancer Immunotherapy: Focus on Lung Cancer.Immune network · 2026Review
- Cancer stem cell-driven drug resistance in colorectal carcinoma: molecular aspects and therapeutic potentials.Molecular cancer · 2026Review
- Integrative network pharmacology and machine learning identify potential targets of indole-3-lactic acid in colorectal cancer.PloS one · 2026Article
- Indole-3-propionic acid suppresses prostate cancer by inducing cell cycle arrest and apoptosis associated with p53 activation.Frontiers in oncology · 2026Article
- Metabolic crosstalk between intestinal microbiota and dendritic cells: from homeostasis to inflammation.Acta biochimica et biophysica Sinica · 2025Review
- The metabolism-immune axis in colorectal cancer: remodeling the tumor microenvironment through metabolite signaling.Frontiers in immunology · 2025Review
- Microbial metabolites and their influence on the tumor microenvironment.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research indicates that abnormal gut microbiota metabolism is linked to colorectal cancer (CRC) progression, but the role of microbiota-related tryptophan metabolism disruption remains unclear. Using metagenomic sequencing and targeted Trp metabolomics, our research identified that CRC patients had abnormal indole-3-lactic acid (ILA) levels, which were related to tumor malignancy. Exogenous ILA administration suppressed CRC development in AOM/DSS induced and xenograft mice models. Furthermore, in vitro experiments demonstrated that ILA inhibits tumor cell proliferation, migration, and anti-apoptotic capabilities. Mechanistically, ILA appears to directly occupy the phosphorylation sites of STAT3, leading to a reduction in intracellular phosphorylated STAT3 (p-STAT3) levels and the inhibition of the HK2 pathway, thereby downregulating glucose metabolism in cancer cells. Notably, this inhibition is independent of the aryl hydrocarbon receptor (AHR). In conclusion, our research findings demonstrate that alterations in tryptophan metabolism among CRC patients can influence tumor progression and reveal a novel mechanism through which ILA exerts its inhibitory effects on CRC. These findings offer new insights into the role of gut microbiota in CRC and identify potential clinical therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.